A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

Abroad (travel likely)RecruitingPHASE2

Conditions

Limited-stage Small Cell Lung Cancer (LS-SCLC) · Chemoradiotherapy · Induction Therapy · Consolidation Immunotherapy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shanghai Chest Hospital, Shanghai, China
Contact: Study coordinator (Xuwei Cai) · zengya1225@126.com · 86021-22200000

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Toripalimab · Surufatinib · Chemoradiotherapy

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Serplulimab Combined With CCRT for LS-SCLC.

Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Beijing, China

Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

Limited-stage Small Cell Lung Cancer (LS-SCLC)

Abroad (travel likely)Recruiting

Beijing, China

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Limited-stage Small Cell Lung Cancer (LS-SCLC)

Abroad (travel likely)RecruitingPHASE3

Goodyear, United States · Tucson, United States